These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34699840)

  • 21. Differential roles of TNFα-TNFR1 and TNFα-TNFR2 in the differentiation and function of CD4
    Yang S; Xie C; Chen Y; Wang J; Chen X; Lu Z; June RR; Zheng SG
    Cell Death Dis; 2019 Jan; 10(1):27. PubMed ID: 30631042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The posttraumatic activation of CD4+ T regulatory cells is modulated by TNFR2- and TLR4-dependent pathways, but not by IL-10.
    Bock M; Bergmann CB; Jung S; Kalbitz M; Relja B; Huber-Wagner S; Biberthaler P; van Griensven M; Hanschen M
    Cell Immunol; 2018 Sep; 331():137-145. PubMed ID: 29954581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE.
    Tsakiri N; Papadopoulos D; Denis MC; Mitsikostas DD; Kollias G
    Eur J Immunol; 2012 Feb; 42(2):403-12. PubMed ID: 22105853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
    Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
    Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
    Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
    J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of a sensitive TNFR2-specific murine assays system.
    Ando D; Kamada H; Inoue M; Taki S; Furuya T; Abe Y; Nagano K; Tsutsumi Y; Tsunoda S
    Pharmazie; 2016 May; 71(5):235-7. PubMed ID: 27348964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein.
    Padutsch T; Sendetski M; Huber C; Peters N; Pfizenmaier K; Bethea JR; Kontermann RE; Fischer R
    Front Pharmacol; 2019; 10():1490. PubMed ID: 31920671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNFR2: A Novel Target for Cancer Immunotherapy.
    Vanamee ÉS; Faustman DL
    Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling.
    Ji W; Li Y; Wan T; Wang J; Zhang H; Chen H; Min W
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2271-9. PubMed ID: 22743059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
    Islam MS; Yang Y; Chen X
    Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
    Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
    J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
    Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
    Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
    Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target.
    Medler J; Wajant H
    Expert Opin Ther Targets; 2019 Apr; 23(4):295-307. PubMed ID: 30856027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity.
    Atretkhany KN; Mufazalov IA; Dunst J; Kuchmiy A; Gogoleva VS; Andruszewski D; Drutskaya MS; Faustman DL; Schwabenland M; Prinz M; Kruglov AA; Waisman A; Nedospasov SA
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):13051-13056. PubMed ID: 30498033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNFα/TNFR2 signaling pathway: an active immune checkpoint for mesenchymal stem cell immunoregulatory function.
    Beldi G; Khosravi M; Abdelgawad ME; Salomon BL; Uzan G; Haouas H; Naserian S
    Stem Cell Res Ther; 2020 Jul; 11(1):281. PubMed ID: 32669116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells.
    Chen X; Oppenheim JJ
    Curr Dir Autoimmun; 2010; 11():119-34. PubMed ID: 20173391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function.
    Housley WJ; Adams CO; Nichols FC; Puddington L; Lingenheld EG; Zhu L; Rajan TV; Clark RB
    J Immunol; 2011 Jun; 186(12):6779-87. PubMed ID: 21572024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.